US10047117 — Preparation and uses of obeticholic acid
Method of Use · Assigned to Intercept Pharmaceuticals Inc · Expires 2033-09-06 · 7y remaining
What this patent protects
This patent protects methods of using obeticholic acid for treating or preventing certain diseases and conditions, including FXR mediated diseases and cholestatic liver disease.
USPTO Abstract
The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
Drugs covered by this patent
- Ocaliva (OBETICHOLIC ACID) · Intercept Pharms Inc
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1854 |
— | Ocaliva |
U-1854 |
— | Ocaliva |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.